The Peptide Field
Menu

4 FDA label tables · Checked

Rash vs placebo, out of 100 people

Forteo label

Placebo4.5%
On Forteo4.9%

In the Forteo label, 4.9% on Forteo had skin rash. On placebo, 4.5% did.

See all 4 tables

Your pick

Rash on Wegovy vs placebo

WegovyFDA-approved product

Wegovy trial in teens with obesity

Row name in our table: Rash

Placebo0%
On Wegovy3%
Who was studied
Children aged 12 and older with obesity. 133 got Wegovy and 67 got placebo.
How long
68 weeks
Source
Wegovy prescribing information on DailyMed . FDA label revised June 2026.

How long were people on Wegovy watched?

Each bar is one set of trials and shows about how long people were in it.

Stated length Range in the source

  1. Egrifta, adults with HIV26 weeks

  2. Forteo, adults with osteoporosis11 months (men), 19 months (women)

  3. Saxenda, teens56 weeks

  4. Wegovy, teens68 weeksYour pick

See every table that lists rash

Every table that lists rash

Each dot is 1 in 100 people.

Reported it Rest of a dose range Did not report it

Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.

Placebo means a shot with no medicine in it. A number in a table is the share of people in a study who reported a problem. It is not your own chance of having it.

FDA-approved medicines

EgriftaFDA-approved product

Egrifta: Adults with HIV and extra belly fat, less common

Row name in our table: Rash

Placebo2%
On Egrifta4%
Who was studied
Adults with HIV and lipodystrophy in placebo-controlled trials. 543 got Egrifta and 263 got placebo.
How long
26 weeks
Source
Egrifta WR prescribing information on DailyMed . FDA label revised March 2025.

ForteoFDA-approved product

Forteo: Women and men with osteoporosis, less common problems

Row name in our table: Skin rash

Placebo4.5%
On Forteo4.9%
Who was studied
1,382 adults aged 28 to 86. 691 got Forteo and 691 got placebo. Everyone also took calcium and vitamin D. The middle trial length was 11 months for men and 19 months for women.
How long
11 months (men), 19 months (women)
Source
Forteo prescribing information on DailyMed . FDA label revised August 2026.

SaxendaFDA-approved product

Saxenda trial in teens with obesity

Row name in our table: Rash

Placebo0%
On Saxenda3.2%
Who was studied
Children aged 12 and older with obesity. None had type 2 diabetes. 125 got Saxenda and 126 got placebo.
How long
56 weeks
Source
Saxenda prescribing information on DailyMed . FDA label revised February 2026.

WegovyFDA-approved product

Wegovy trial in teens with obesity

Row name in our table: Rash

Placebo0%
On Wegovy3%
Who was studied
Children aged 12 and older with obesity. 133 got Wegovy and 67 got placebo.
How long
68 weeks
Source
Wegovy prescribing information on DailyMed . FDA label revised June 2026.

How long were people watched?

Each bar is one set of trials and shows about how long people were in it.

Stated length Range in the source

  1. Egrifta, adults with HIV26 weeks

  2. Forteo, adults with osteoporosis11 months (men), 19 months (women)

  3. Saxenda, teens56 weeks

  4. Wegovy, teens68 weeks

Trials can miss rare harms and harms that take years to appear.

Other side effects

Pick a medicine and side effect

Where the numbers come from

Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.

We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row keeps the name it has in our side effect table.

The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.

Report a side effect

You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.

Did this page answer your question?